Substituted spirochromanone derivatives
View Patent ↗The invention relates to a compound of a general formula (I): wherein Ar 1 represents a group formed from an aromatic ring selected from a group consisting of indole, 1H-indazole, 2H-indazole, 1H-thieno[2,3-c]pyrazole, 1H-pyrazolo[3,4-b]pyridine, benzo[b]furan, benzimidazole, benzoxazole, 1,2-benzisoxazole and imidazo[1,2-a]pyridine; R 1 and R 2 each represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a cyclo-C3-C6 alkyloxy group, a C2-C7 alkanoyl group, a halo-C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a halo-C2-C7 alkoxycarbonyl group, a cyclo-C3-C6 alkyloxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q 1 -N(R a )-Q 2 -R b ; an optionally-substituted C1-C6 alkyl, aryl or heterocyclic group; or a C1-C6 alkyl or C2-C6 alkenyl group having the aryl or heterocyclic group; R 3 and R 4 each represent a hydrogen atom, a halogen atom, a nitro group, a cyclo-C3-C6 alkyl group, a carbamoyl group optionally substituted with a C1-C6 alkyl or cyclo-C3-C6 alkyl group, or a group of —N(R e )R f ; an optionally-substituted C2-C7 alkanoyl, C1-C6 alkoxy, C2-C7 alkoxycarbonyl, cyclo-C3-C6 alkyloxycarbonyl, C1-C6 alkylsulfonyl, C1-C6 alkylthio, cyclo-C3-C6 alkyloxy, cyclo-C3-C6 alkyl-C1-C6 alkoxy, cyclo-C3-C6 alkylsulfonyl, cyclo-C3-C6 alkylthio or cyclo-C3-C6 alkyl-C1-C6 alkylthio group; or an optionally-substituted C1-C6 alkyl group; T and U each represent a nitrogen atom or a methine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.
1. A compound represented by a general formula (I-2):
wherein,
Ar 1 represents a group formed from an aromatic ring selected from a group consisting of indole, 1H-indazole, 2H-indazole, 1H-thieno[2,3-c]pyrazole, 1H-pyrazolo[3,4-b]pyridine, benzo[b]furan, benzimidazole, benzoxazole, 1,2-benzisoxazole and imidazo[1,2-a]pyridine, having R 30 and R 40 , and optionally having a substituent selected from a group consisting of a halogen atom, a nitro group, a cyano group, a hydroxyl group, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group, a cyclo-C3-C6 alkyl group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a C1-C6 alkylthio group, a carboxyl group and a carbamoyl group;
R 1 represents an aryl or heterocyclic group optionally having a substituent selected from a group consisting of a halogen atom, a hydroxyl group, an oxo group, a thioxo group, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group, a C2-C7 alkanoyloxy-C1-C6 alkyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a formyl group, a carboxyl group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkylsulfonyl group and a group of —CO—N(R c )R d ; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group;
R 20 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, or a C1-C6 alkoxy group;
R 30 and R 40 each independently represent a halogen atom, a nitro group, a cyclo-C3-C6 alkyl group, a carbamoyl group optionally substituted with a C1-C6 alkyl or cyclo-C3-C6 alkyl group, or a group of —N(R e )R f ; or
a C2-C7 alkanoyl group, a C1-C6 alkoxy group, a C2-C7 alkoxycarbonyl group, a cyclo-C3-C6 alkyloxycarbonyl group, a C1-C6 alkylsulfonyl group, a C1-C6 alkylthio group, a cyclo-C3-C6 alkyloxy group, a cyclo-C3-C6 alkyl-C1-C6 alkoxy group, a cyclo-C3-C6 alkylsulfonyl group, a cyclo-C3-C6 alkylthio group or a cyclo-C3-C6 alkyl-C1-C6 alkylthio group, optionally substituted with a halogen atom or a hydroxyl group, wherein the cyclo-C3-C6 alkyl group in the cyclo-C3-C6 alkyloxycarbonyl group, the cyclo-C3-C6 alkyloxy group, the cyclo-C3-C6 alkyl-C1-C6 alkoxy group, the cyclo-C3-C6 alkylsulfonyl group, the cyclo-C3-C6 alkylthio group or the cyclo-C3-C6 alkyl-C1-C6 alkylthio group may be interrupted by an oxygen atom, a sulfur atom or an imino group; or
a C1-C6 alkyl group optionally having a substituent selected from a group consisting of a halogen atom, a hydroxyl group and a cyclo-C3-C6 alkyl group;
R c and R d each independently represent a hydrogen atom, a C1-C6 alkyl group, or a halo-C1-C6 alkyl group; and
R e and R f each independently represent a hydrogen atom, a C1-C6 alkyl group, or a halo-C1-C6 alkyl group, or taken together, they may form a C2-C5 alkylene group optionally interrupted by an oxygen atom, a sulfur atom or an imino group;
or a pharmaceutically acceptable salt.
2. The compound as claimed in claim 1 , wherein R 30 and R 40 each independently represent a nitro group, a cyclo-C3-C6 alkyl group, a carbamoyl group optionally substituted with a C1-C6 alkyl or cyclo-C3-C6 alkyl group, a C1-C6 alkoxy group optionally substituted with a hydroxyl group, or a C1-C6 alkyl group optionally substituted with a hydroxyl group; or a pharmaceutically acceptable salt or ester thereof.
3. The compound as claimed in claim 1 , wherein R 30 is a C1-C6 alkoxy group optionally substituted with a hydroxyl group; and R 40 is a cyclo-C3-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 alkyl group; or a pharmaceutically acceptable salt.
4. The compound as claimed in claim 1 , wherein R 1 is an aryl or a heterocyclic group optionally having a substituent selected from a group consisting of a halogen atom, a hydroxyl group, an oxo group, a thioxo group, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group, a C2-C7 alkanoyloxy-C1-C6 alkyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a formyl group, a carboxyl group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkylsulfonyl group and a group of —CO—N(R c )R d ; or a pharmaceutically acceptable salt.
5. The compound as claimed in claim 4 , wherein the aryl or heterocyclic group for R 1 , which may have a substituent selected from a group consisting of a halogen atom, a hydroxyl group, an oxo group, a thioxo group, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group, a C2-C7 alkanoyloxy-C1-C6 alkyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a formyl group, a carboxyl group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkylsulfonyl group and a group of —CO—N(R c )R d , is a phenyl group optionally substituted with a carboxyl group, a C2-C7 alkoxycarbonyl group or a group of —CO—N(R c )R d ; a pyrazolyl group optionally substituted with a C1-C6 alkyl group; a 1,2,4-triazolyl group; a tetrazolyl group optionally substituted with a C2-C7 alkanoyloxy-C1-C6 alkyl group; a pyridyl group optionally substituted with a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, a carboxyl group, a C2-C7 alkoxycarbonyl group or a group of —CO—N(R c )R d ; a pyrimidinyl group; a dihydro-1,2,4-triazolyl group optionally substituted with an oxo group; a dihydro-1,2,4-oxadiazolyl group optionally substituted with an oxo group; or a dihydropyridyl group optionally substituted with an oxo group; or a pharmaceutically acceptable salt.
6. The compound as claimed in claim 4 , wherein the aryl or heterocyclic group for R 1 , which may have a substituent selected from a group consisting of a halogen atom, a hydroxyl group, an oxo group, a thioxo group, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group, a C2-C7 alkanoyloxy-C1-C6 alkyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a formyl group, a carboxyl group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkylsulfonyl group and a group of —CO—N(R c )R d , is a phenyl group optionally substituted with a carboxyl group or a group of —CO—N(R c )R d ; a pyrazolyl group optionally substituted with a C1-C6 alkyl group; a 1,2,4-triazolyl group; a tetrazolyl group optionally substituted with a C2-C7 alkanoyloxy-C1-C6 alkyl group; a pyridyl group optionally substituted with a C1-C6 alkoxy group, a carboxyl group or a group of —CO—N(R c )R d ; a dihydro-1,2,4-triazolyl group optionally substituted with an oxo group; or a dihydro-1,2,4-oxadiazolyl group optionally substituted with an oxo group; or a pharmaceutically acceptable salt.
7. The compound as claimed in claim 4 , wherein the aryl or heterocyclic group for R 1 , which may have a substituent selected from a group consisting of a halogen atom, a hydroxyl group, an oxo group, a thioxo group, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group, a C2-C7 alkanoyloxy-C1-C6 alkyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a formyl group, a carboxyl group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkylsulfonyl group and a group of —CO—N(R c )R d , is a phenyl group optionally substituted with a carboxyl group or a group of —CO—N(R c )R d ; a tetrazolyl group optionally substituted with a C2-C7 alkanoyloxy-C1-C6 alkyl group; a pyridyl group optionally substituted with a C1-C6 alkoxy group, a carboxyl group or a group of —CO—N(R c )R d ; or a dihydro-1,2,4-oxadiazolyl group optionally substituted with an oxo group; or a pharmaceutically acceptable salt.
8. The compound as claimed in claim 1 , wherein R 1 is a pyridyl group substituted with a carboxyl group; or a pharmaceutically acceptable salt.
9. The compound as claimed in claim 1 , which is selected from the following:
(1) 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidine]-4-one,
(2) 1′-[(3-Cyclopropyl-8-methoxyimidazo[1,2-a]pyridin-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(3) 1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)spiro[chroman-2,4′-piperidin]-4-one,
(4) 1′-{[1-Ethyl-4-(2-hydroxyethoxy)-1H-indol-6-yl]carbonyl}-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(5) Sodium 3-{1′-[(1-cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}benzoate,
(6) 5-{1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid,
(7) 5-{1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxo-3,4-dihydrospiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid sodium salt,
(8) 1′-{[1,4-Dimethoxy-1H-indol-6-yl]carbonyl}-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(9) 1′-{[1,4-Dimethoxy-1H-indol-6-yl]carbonyl}-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one sodium salt,
(10) 1′-[(1-Ethyl-4-methoxy-1H-indazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(11) 1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(12) 1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one sodium salt,
(13) 1′-[(1-Cyclopropyl-4-ethoxy-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(14) 1′-[(1-Cyclopropyl-4-ethoxy-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one sodium salt,
(15) 1′-[(1,4-Diethoxy-1H-indazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(16) 1′-[(3-Chloro-1-cyclopropyl-4-ethoxy-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(17) 1′-[(1-Cyclopropyl-4-ethoxy-3-methyl-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(18) 3-(1′-{[1-Cyclopropyl-4-(2-hydroxyethoxy)-1H-indol-6-yl]carbonyl}-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl)benzoic acid,
(19) 5-{1′-[(1-Cyclopropyl-4-ethoxy-1H-indol-6-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid sodium salt,
(20) 2-{1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}isonicotinic acid sodium salt,
(21) 4-{1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}pyridine-2-carboxylic acid sodium salt,
(22) 5-{1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}pyridine-2-carboxylic acid sodium salt,
(23) 5-{1′-[(1-Cyclopropyl-4-methoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid sodium salt,
(24) 5-{1′-[(3-Chloro-1-cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid sodium salt,
(25) 1′-[(4-Acetyl-7-methoxy-1-benzofuran-2-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(26) 1′-[(1-Ethyl-3-methyl-1H-thieno[2,3-c]pyrazol-5-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(27) 5-{1′-[(1-Cyclopropyl-4-methoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid,
(28) 1′-[(4-Methoxy-1-methyl-1H-pyrazolo[3,4-b]pyridin-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(30) 1′-[(3-Chloro-1-cyclopropyl-7-ethoxy-1H-indol-5-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(31) 1′-[(3-Cyclopropyl-7-ethoxy-1,2-benzisoxazol-5-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(32) 1′-[(2-Cyclopropyl-7-ethoxy-1,3-benzoxazol-5-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(33) 1-Cyclopropyl-4-ethoxy-6-{[4-oxo-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-1′-yl]carbonyl}-1H-indole-3-carboxamide,
(36) 1′-{[1-Cyclopropyl-4-(2-hydroxyethoxy)-1H-indol-6-yl]carbonyl}-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(37) 1-Cyclopropyl-4-ethoxy-N-methyl-6-{[4-oxo-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-1′-yl]carbonyl}-1H-indole-3-carboxamide,
(38) Methyl 3-(1′-{[3-carbamoyl-1-cyclopropyl-4-ethoxy-1H-indol-6-yl]carbonyl}-4-oxospiro[chroman-2,4′-piperidin]-6-yl)benzoate,
(39) 3-(1′-{[3-Carbamoyl-1-cyclopropyl-4-ethoxy-1H-indol-6-yl]carbonyl}-4-oxospiro[chroman-2,4′-piperidin]-6-yl)benzoic acid,
(40) 1-Cyclopropyl-4-ethoxy-6-{[4-oxo-6-(1H-pyrazol-4-yl)spiro[chroman-2,4′-piperidin]-1′-yl]carbonyl}-1H-indole-3-carboxylic acid,
(41) 1-Cyclopropyl-4-ethoxy-6-({6-[(1-methyl-1H-pyrazol-5-yl)amino]-4-oxospiro[chroman-2,4′-piperidin]-1′-yl}carbonyl)-1H-indole-3-carboxylic acid,
(42) 4-{1′-[(1-Cyclopropyl-4-methoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}pyridine-2-carboxylic acid,
(43) 5-{1′-[(1-Cyclopropyl-4-methoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}-2-methylnicotinic acid,
(44) 6-{1′-[(1-Cyclopropyl-4-methoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid,
(45) 5-{1′-[(1-Cyclopropyl-4-ethoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid,
(46) 4-{1′-[(1-Cyclopropyl-4-ethoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}pyridine-2-carboxylic acid,
(47) 5-{1′-[(1-Cyclopropyl-4-ethoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid sodium salt,
(48) 5-{1′-[(1,4-Dimethoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid,
(49) 6-(5-Bromopyridin-3-yl)-1′-[(1-cyclopropyl-4-methoxy-3-methyl-1H-indol-6-yl)carbonyl]spiro[chroman-2,4′-piperidin]-4-one,
(50) Methyl 5-{1′-[(1-cyclopropyl-4-methoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}nicotinate,
(51) 1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-6-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)spiro[chroman-2,4′-piperidin]-4-one,
(53) Sodium 5-{1′-[(1-cyclopropyl-4-ethoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}-2-methylnicotinate,
(54) 1′-[(1-Ethyl-4-morpholin-4-yl-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(55) 1′-[(1-Cyclopropyl-4-methoxy-3-methyl-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(56) 1′-[(1-Ethyl-4-methoxy-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(57) 5-{1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}-4H-1,2,4-triazole-3-carboxamide,
(58) 1′-[(1,3-Diethyl-7-methoxy-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one,
(59) 5-{1′-[(6-Cyclopropyl-1-isopropyl-1H-pyrazolo[3,4-b]pyridin-4-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid, or
(60) 1′-[(1-Cyclopropyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one;
or a pharmaceutically acceptable salt.
10. The compound of claim 1 which is 3-{1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}benzoic acid, or a pharmaceutically acceptable salt or ester thereof.
11. The compound of claim 1 which is 5-{1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid, or a pharmaceutically acceptable salt or ester thereof.
12. The compound of claim 1 which is 1′-[(1-Cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one, or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1 which is 1′-[(1-Cyclopropyl-4-ethoxy-3-methyl-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one, or a pharmaceutically acceptable salt thereof.
14. The compound of claim 1 which is 5-{1′-[(1-Cyclopropyl-4-methoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid, or a pharmaceutically acceptable salt.
15. A pharmaceutical composition comprising a therapeutically effective amount of the compound of formula (I) of claim 1 or a pharmaceutically acceptable salt, and a pharmaceutically acceptable additive.